Status:
TERMINATED
Efficacy of Higher Albendazole and Ivermectin Doses on Wuchereria Bancrofti Microfilarial Clearance in Malawi
Lead Sponsor:
London School of Hygiene and Tropical Medicine
Collaborating Sponsors:
Emory University
Conditions:
Lymphatic Filariasis
Eligibility:
All Genders
18-55 years
Phase:
NA
Brief Summary
Albendazole and ivermectin are currently used in combination for annual mass treatment of lymphatic filariasis in Africa. Although the drugs have been donated, the cost of such programmes is very high...
Detailed Description
The proposed study will enrol up to 120 volunteers with microfilaremic Wuchereria bancrofti infection who would be randomized to receive standard annual treatment (albendazole 400 mg + ivermectin 200 ...
Eligibility Criteria
Inclusion
- understand and sign informed consent
- willing to undergo night blood sampling every 6 months for 2 years
- Age 18 to 55 years
- Haemoglobin of equal or above 9g/dl
- Microfilarial level of equal or above 80mg/dl
Exclusion
- Non- consenting
- Pregnancy or lactation
- Treatment with albendazole or ivermectin within the previous 6 months
- Known allergy to the study drugs
Key Trial Info
Start Date :
January 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2012
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT01213576
Start Date
January 1 2009
End Date
February 1 2012
Last Update
February 27 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Karonga Prevention Study
Karonga, Malawi